Tocilizumab stabilizes lung function in SSc-related interstitial lung disease

868826

February 23, 2021

2 min read

Source/Disclosures

Published by:

Disclosures: Roofeh reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tocilizumab treatment in early interstitial lung disease, with progressive skin involvement related to systemic sclerosis, was able to stabilize forced vital capacity over 48 weeks, according to data published in Arthritis & Rheumatology.

“The majority of systemic sclerosis patients will develop interstitial lung disease (SSc-ILD),” David Roofeh, MD, of the University of Michigan, and colleagues wrote. “Those at risk for progressive disease have an archetype: Early, diffuse cutaneous systemic sclerosis (dcSSc), with elevated acute phase reactants like C-reactive protein (CRP) and topoisomerase-1 antibody positivity…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close